Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Micro Therapeutics, Inc. d/b/a ev3 Neurovascular

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Micro Therapeutics, Inc. d/b/a ev3 Neurovascular

Regulatory records
5
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 5 FDA records to the applicant name Micro Therapeutics, Inc. d/b/a ev3 Neurovascular. 2 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 14, 2025 to Jul 21, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code OUT appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P100018, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 9775 Toledo Way, Irvine, CA, 92618. Recorded on P100018/S055, decision dated Jul 21, 2026.

Changes described in PMA records

P100018/S052: PIPELINE EMBOLIZATION DEVICE

FDA’s recorded scope: Approval of claims regarding reduced material thrombogenicity of a proprietary surface modification for the Pipeline Flex Embolization Device with Shield Technology and Pipeline Vantage Embolization Device with Shield Technology supported by acute benchtop in-vitro testing.

Feb 20, 2026 · Real-Time Process

P100018/S048: Pipeline Vantage Embolization Device with Shield Technology

FDA’s recorded scope: Approval for changes to the post-approval study (PAS) protocol for Pipeline Vantage device following the removal of the Vantage 027 devices, including updates to include additional follow-up imaging to assess for braid deformation events.

Aug 14, 2025 · Normal 180 Day Track No User Fee

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.